Your browser doesn't support javascript.
loading
Neddylation, a novel paradigm in liver cancer.
Delgado, Teresa Cardoso; Barbier-Torres, Lúcia; Zubiete-Franco, Imanol; Lopitz-Otsoa, Fernando; Varela-Rey, Marta; Fernández-Ramos, David; Martínez-Chantar, María-Luz.
Afiliação
  • Delgado TC; CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain.
  • Barbier-Torres L; CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain.
  • Zubiete-Franco I; Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Lopitz-Otsoa F; CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain.
  • Varela-Rey M; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY, USA.
  • Fernández-Ramos D; CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain.
  • Martínez-Chantar ML; CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain.
Article em En | MEDLINE | ID: mdl-30050997
ABSTRACT
Liver cancer is the sixth most prevailing cancer worldwide. Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, has a rather heterogeneous pathogenesis making it highly refractive to current therapeutic approaches. Hence, HCC patients have a poor and gloomy prognosis making liver cancer the second leading cause of global cancer-related deaths. On this basis, a more global mechanism, such as post-translational modifications (PTMs) of proteins, may provide a valuable therapeutic approach for HCC clinical management by simultaneously regulating multiple disrupted signaling pathways. In the last years, the ubiquitin-like molecule NEDD8 (Neural precursor cell-expressed developmentally downregulated-8) conjugation pathway, neddylation, was shown to be aberrant in HCC patients with a significant positive correlation found among global levels of neddylation and poorer prognosis. Even though the best-established role for NEDD8 is the activation of ubiquitin E3 ligase family of cullin-RING ligases, the putative role for other NEDD8 substrates has been explored in recent years leading to the identification of novel neddylation targets in HCC. Importantly, treatment with the small pharmacological inhibitor Pevonedistat (MLN4924) (Millennium Pharmaceuticals, Takeda Pharmaceutical), currently in clinical trials for the treatment of some types of leukemias and other advanced solid tumors, was shown to suppress the outgrowth of hepatoma cells and liver cancer in pre-clinical mouse models. Overall, considering that the neddylation inhibitor Pevonedistat was well-tolerated and displayed a significant antitumor effect in pre-clinical models, combinatory pharmacological treatment based on Pevonedistat are highly recommended to enter clinical trials targeting advanced HCC.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Transl Gastroenterol Hepatol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Transl Gastroenterol Hepatol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha